Halle M, Schöbel C, Winzer EB, et al. - Sacubitril/valsartan administration for short-term (12 weeks) in heart failure with reduced ejection fraction (HFrEF) patients did not provide significant benefits on peak VO ₂ (peak oxygen consumption) when compared with treatment with enalapril.

• In this randomized, double-blind, active-controlled study (ACTIVITY-HF), a total of 201 ambulatory HFrEF patients were randomized (1:1) to receive sacubitril/valsartan 97/103 mg bid (n = 103) or enalapril 10 mg bid (n = 98).

• Similar change in peak VO2 from baseline to Week 12 was evident between both treatment arms.

• In terms of minute ventilation to carbon dioxide production slope, exercise capacity at first ventilatory threshold or Borg scale at either Week 6 or Week 12, there were no significant differences between the two treatment groups.

• The sacubitril/valsartan group exhibited lower change in heart rate at first ventilatory threshold vs the enalapril group at Week 12.

• Sacubitril/valsartan displayed a safety profile comparable to enalapril.